间充质干细胞来源的胞外囊泡治疗代谢相关性脂肪性肝病的研究进展  

Advances in mesenchymal stem cell-derived extracellular vesicles for the treatment of metabolism-associated fatty liver disease

作　　者：周慧媛 宋红丽[2] Zhou Huiyuan;Song Hongli(Tianjin Medical University First Center Clinical College,Tianjin 300192,China;Tianjin First Center Hospital,Liver Transplantation Department Tianjin Key Laboratory of Organ Transplantation Tianjin Organ Transplantation Clinical Medical Research Center,Tianjin 300192,China)

机构地区：[1]天津医科大学一中心临床学院,天津300192 [2]天津市第一中心医院肝移植科、天津市器官移植重点实验室、天津市器官移植临床医学研究中心,天津300192

出　　处：《中华实验外科杂志》2023年第10期2116-2120,共5页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金(82070639)。

摘　　要：代谢相关性脂肪性肝病(MAFLD)被认为是一种常见的慢性肝脏疾病,现已经成为西方国家肝移植第二大适应症,目前仍缺乏有效的治疗方法。间充质干细胞(MSCs)治疗肝脏疾病临床疗效已得到证实,但由于其移植定植率低和分化方向不确定性等,临床应用面临争议。MSCs来源的胞外囊泡(EVs)作为一种脂质双层囊泡结构,能够通过其携带的活性物质和自身功能,发挥调节肝脏代谢、调节免疫、调节肝细胞增殖分化及调节细胞间信息交流等作用,是一种比MSCs更安全的无细胞疗法。本文主要对MSCs来源的EVs治疗MAFLD相关情况进行综述。Metabolic-dysfunction-associated fatty liver disease(MAFLD)is considered a common chronic liver disease and is now the second most common indication for liver transplantation in Western countries,and there is still a lack of effective therapeutic approaches.The clinical efficacy of MSCs for liver disease has been confirmed,but their clinical application is controversial due to their low transplantation colonization rate and uncertainty of differentiation direction.It is a safer cell-free therapy than MSCs.In this paper,we review the treatment of MAFLD with MSCs-EVs.

关 键 词：代谢相关性脂肪性肝病 间充质干细胞 胞外囊泡 无细胞疗法 

分 类 号：R575[医药卫生—消化系统]